Histogen Inc. (HSTO)
After hours:
| Previous close | 2.3200 |
| Open | 2.1900 |
| Bid | 2.0500 x 1100 |
| Ask | 2.3700 x 1100 |
| Day's range | 2.1700 - 2.3000 |
| 52-week range | 2.0600 - 22.2000 |
| Volume | |
| Avg. volume | 163,867 |
| Market cap | 113.886M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4930 |
| Earnings date | 09 Mar 2022 - 14 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.25 |
- GlobeNewswire
Histogen Announces 1-for-20 Reverse Stock Split
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective at 4:01 p.
- GlobeNewswire
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. On-Demand Presentation DetailsD
- GlobeNewswire
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
Received $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the first
